31 Participants Needed

Brentuximab Vedotin + Nivolumab for Hodgkin's Lymphoma

Recruiting at 4 trial locations
AH
Overseen ByAlex Herrera, MD
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial
Breakthrough TherapyThis drug has been fast-tracked for approval by the FDA given its high promise

Trial Summary

What is the purpose of this trial?

This phase II trial investigates how well brentuximab vedotin and nivolumab work in treating patients with classical Hodgkin lymphoma that has come back after initial treatment (relapsed) or has not responded to initial treatment (refractory). Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. Nivolumab is an antibody that enhances the immune system to better fight Hodgkin lymphoma cells. Giving brentuximab vedotin and nivolumab may be able to defer stem cell transplant treatment and spare the considerable cost and toxicity on transplantation.

Will I have to stop taking my current medications?

The trial protocol does not specify if you need to stop taking your current medications. However, you cannot take certain investigational therapies or systemic treatments like high-dose corticosteroids within 14 days of starting the study drugs. It's best to discuss your specific medications with the study team.

What data supports the effectiveness of the drug combination Brentuximab Vedotin and Nivolumab for treating Hodgkin's Lymphoma?

Research shows that Brentuximab Vedotin, when used alone or in combination with other drugs, has been effective in treating Hodgkin's Lymphoma, especially in patients who have relapsed after previous treatments. It has shown high response rates and prolonged survival in various trials, making it a promising option for those with difficult-to-treat cases.12345

Is the combination of Brentuximab Vedotin and Nivolumab safe for humans?

Brentuximab Vedotin is generally well tolerated, with common side effects like peripheral neuropathy (nerve damage causing tingling or numbness) and neutropenia (low white blood cell count). Nivolumab, an anti-PD1 immunotherapy, can cause immune-related side effects that are varied and unpredictable, such as skin rash and lung issues.25678

How is the drug combination of Brentuximab Vedotin and Nivolumab unique for treating Hodgkin's Lymphoma?

This drug combination is unique because it combines Brentuximab Vedotin, an antibody-drug that targets a specific protein on cancer cells, with Nivolumab, which helps the immune system attack cancer cells. This approach is particularly useful for patients who have not responded to other treatments or are not suitable for standard chemotherapy.1491011

Research Team

Alex Herrera, M.D., Chief, Division of ...

Alex F. Herrera

Principal Investigator

City of Hope Medical Center

Eligibility Criteria

This trial is for adults with classical Hodgkin lymphoma that has returned or didn't respond to first treatment. They must have had only one prior therapy, no severe allergies to the drugs being tested, and no active major diseases like heart problems or uncontrolled infections. Participants need normal organ function tests and agree to use birth control.

Inclusion Criteria

Agreement by women and men of childbearing potential* to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 5 months (women) or 7 months (men) after the last dose of protocol therapy
I was treated with BV or anti-PD-1/PD-L1, achieved complete remission, and haven't relapsed in 6 months.
I am not eligible for a stem cell transplant due to my age, health conditions, or personal choice.
See 21 more

Exclusion Criteria

You had a severe allergic reaction (grade 3 or higher) to brentuximab vedotin or nivolumab in the past.
I have had progressive multifocal leukoencephalopathy in the past.
My cervical cancer is in its early stages and has not spread.
See 26 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive brentuximab vedotin and nivolumab intravenously every 21 days for up to 16 cycles

48 weeks
16 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

60 months
8 visits (in-person)

Treatment Details

Interventions

  • Brentuximab Vedotin
  • Nivolumab
Trial OverviewThe study is testing brentuximab vedotin (an antibody-drug conjugate) combined with nivolumab (a drug boosting the immune system) in patients with relapsed/refractory classical Hodgkin lymphoma. The goal is to see if this combo can delay or replace stem cell transplant treatments.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Treatment (brentuximab vedotin, nivolumab)Experimental Treatment2 Interventions
Patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity.

Brentuximab Vedotin is already approved in United States, European Union for the following indications:

🇺🇸
Approved in United States as Adcetris for:
  • Hodgkin lymphoma
  • Systemic anaplastic large cell lymphoma
  • Primary cutaneous anaplastic large cell lymphoma
  • CD30-expressing mycosis fungoides
  • Peripheral T-cell lymphoma
🇪🇺
Approved in European Union as Adcetris for:
  • Hodgkin lymphoma
  • Systemic anaplastic large cell lymphoma
  • Cutaneous T-cell lymphoma

Find a Clinic Near You

Who Is Running the Clinical Trial?

City of Hope Medical Center

Lead Sponsor

Trials
614
Recruited
1,924,000+

National Cancer Institute (NCI)

Collaborator

Trials
14,080
Recruited
41,180,000+

Findings from Research

In a phase 1/2 trial involving 64 patients with relapsed or refractory Hodgkin lymphoma, the combination of brentuximab vedotin with nivolumab showed a high overall response rate of 89%, indicating strong efficacy in treating this type of cancer.
The study also reported varying levels of treatment-related adverse events, with the triplet therapy group experiencing the highest rate of severe side effects (50%), highlighting the importance of balancing efficacy with safety in treatment regimens.
Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.Diefenbach, CS., Hong, F., Ambinder, RF., et al.[2021]
Brentuximab vedotin is an effective treatment for relapsed or refractory classical Hodgkin lymphoma, showing high response rates and durable outcomes in both clinical trials and real-world settings.
In the phase 3 AETHERA trial, brentuximab vedotin significantly prolonged progression-free survival compared to placebo after autologous stem cell transplant, reducing the risk of disease progression or death by 43% over a median follow-up of 30 months.
Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma.Scott, LJ.[2020]
In a study of 1334 patients with untreated stage III or IV Hodgkin's lymphoma, those treated with brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) showed a significant overall survival advantage compared to those receiving the standard ABVD regimen, with a 6-year survival rate of 93.9% versus 89.4%.
A+AVD also resulted in longer progression-free survival and fewer patients requiring subsequent therapies, although it was associated with a higher incidence of peripheral neuropathy, which mostly resolved by the last follow-up.
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma.Ansell, SM., Radford, J., Connors, JM., et al.[2022]

References

Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. [2021]
Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma. [2020]
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma. [2022]
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. [2023]
Brentuximab vedotin: a review of its use in patients with hodgkin lymphoma and systemic anaplastic large cell lymphoma following previous treatment failure. [2021]
[Toxicity of targeted therapies and immunotherapy with checkpointinhibitors in Hodgkin lymphoma]. [2023]
Population PK and Exposure-Response Relationships for the Antibody-Drug Conjugate Brentuximab Vedotin in CTCL Patients in the Phase III ALCANZA Study. [2019]
A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma. [2019]
Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma. [2020]
Efficacy and safety of nivolumab combined with brentuximab vedotin after nivolumab monotherapy failure in patients with relapsed and refractory classic Hodgkin lymphoma. [2023]
Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial. [2020]